Kairax — CE-Certified HA Filler with Lidocaine (Fine / Deep / Sub-Q)

Kairax is Victoria Sun’s CE-certified HA dermal filler range — 24 mg/mL cross-linked HA + 0.3% lidocaine using a hybrid traditional + mechanical cross-linking process for enhanced viscoelasticity. Three variants (Fine, Deep, Sub-Q) cover the full spectrum from fine wrinkle correction to deep facial contouring. CE approved for EU/international distribution.

Kairax CE Certified HA Filler with Lidocaine is manufactured by Victoria Sun Inc., a South Korea-based medical device and pharmaceutical company established in 2012. The product is part of the Kairax dermal filler range, which is distributed across multiple international markets. Regulatory status: CE marked · KFDA registered · GMP certified.

Kairax CE Certified HA Filler with Lidocaine contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Victoria Sun Inc.’s Traditional + Mechanical Cross-Linking Hybrid technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Victoria Sun Inc.’s clinical data, Kairax CE Certified HA Filler with Lidocaine delivers Up to 12 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Variant-dependent (fine / deep / sub-q) placement typically delivers the longer end of the duration range.

Kairax CE Certified HA Filler with Lidocaine is engineered for variant-dependent (fine / deep / sub-q) placement. The standard recommended needle is 27G-25G (variant-dependent), supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Kairax CE Certified HA Filler with Lidocaine regulatory status: CE marked · KFDA registered · GMP certified. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Kairax CE Certified HA Filler with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Kairax CE Certified HA Filler with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Kairax CE Certified HA Filler with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Variant selection depends on target tissue depth and aesthetic goal. Kairax Fine (lowest viscoelasticity) for superficial dermal placement — fine lip wrinkles, periorbital lines, crow’s feet. Kairax Deep (medium viscoelasticity) for mid-to-deep dermal placement — glabella, nasolabial folds, marionette lines, nose and forehead contour. Kairax Sub-Q (highest viscoelasticity) for subcutaneous placement — cheek augmentation, jawline contouring, body work. All three share 24 mg/mL HA + 0.3% lidocaine base; differentiation is cross-linking density.